Literature DB >> 11343219

RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression.

W A Paxton1, A U Neumann, S Kang, L Deutch, R C Brown, R A Koup, S M Wolinsky.   

Abstract

Several chemokine and chemokine receptor parameters were measured in peripheral blood mononuclear cells obtained from patients before they became infected with human immunodeficiency virus type 1 (HIV-1). After HIV-1 infection, the parameters were compared with plasma HIV-1 RNA levels and with rates of CD4(+) lymphocyte decline. Patients who were heterozygous for the Delta32CCR5 allele had significantly higher levels of RANTES production from their CD4(+) lymphocytes than did patients who did not carry the Delta32CCR5 allele (P=.01). Higher RANTES production levels from ex vivo-activated CD4(+)-enriched lymphocytes, but not CD8(+) lymphocytes, correlated with lower plasma HIV-1 RNA levels 9-12 months after infection (P= .01) and with slower rates of CD4(+) lymphocyte decline (P= .002). CCR5 expression levels on ex vivo-activated CD4(+) lymphocytes did not correlate with markers of disease progression. These results further support the hypothesis that chemokine production levels are associated with HIV-1 replication in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343219     DOI: 10.1086/320701

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

2.  M-tropic HIV envelope protein gp120 exhibits a different neuropathological profile than T-tropic gp120 in rat striatum.

Authors:  Alessia Bachis; Maria I Cruz; Italo Mocchetti
Journal:  Eur J Neurosci       Date:  2010-07-28       Impact factor: 3.386

3.  The entry of entry inhibitors: a fusion of science and medicine.

Authors:  John P Moore; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

4.  Stimulation of toll-like receptor 2 in mononuclear cells from HIV-infected patients induces chemokine responses: possible pathogenic consequences.

Authors:  L Heggelund; J K Damås; A Yndestad; A M Holm; F Mūller; E Lien; T Espevik; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

5.  Modulating influence on HIV/AIDS by interacting RANTES gene variants.

Authors:  Ping An; George W Nelson; Lihua Wang; Sharyne Donfield; James J Goedert; John Phair; David Vlahov; Susan Buchbinder; William L Farrar; William Modi; Stephen J O'Brien; Cheryl A Winkler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-11       Impact factor: 11.205

6.  Interleukin-7-dependent production of RANTES that correlates with human immunodeficiency virus disease progression.

Authors:  Anuska Llano; Jordi Barretina; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

Authors:  Ronald S Veazey; Per Johan Klasse; Thomas J Ketas; Jacqueline D Reeves; Michael Piatak; Kevin Kunstman; Shawn E Kuhmann; Preston A Marx; Jeffrey D Lifson; Jason Dufour; Megan Mefford; Ivona Pandrea; Steven M Wolinsky; Robert W Doms; Julie A DeMartino; Salvatore J Siciliano; Kathy Lyons; Martin S Springer; John P Moore
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

8.  Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma.

Authors:  Thomas B Campbell; Kristina Schneider; Terri Wrin; Christos J Petropoulos; Elizabeth Connick
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors.

Authors:  Erika Billick; Christoph Seibert; Pavel Pugach; Tom Ketas; Alexandra Trkola; Michael J Endres; Nicholas J Murgolo; Elizabeth Coates; Gregory R Reyes; Bahige M Baroudy; Thomas P Sakmar; John P Moore; Shawn E Kuhmann
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Authors:  Alexandra Trkola; Herbert Kuster; Christine Leemann; Claudia Ruprecht; Beda Joos; Amalio Telenti; Bernhard Hirschel; Rainer Weber; Sebastian Bonhoeffer; Huldrych F Günthard
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.